Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a "shock and kill" strategy for ART-free virological control: a phase II single-arm study.

Compared with the baseline, the total HIV DNA exhibited an increasing trend at week 4 ( P = 0.014), but subsequently demonstrated a declining trajectory at week 8, ultimately returning to baseline levels by week 12 and week 24 (Fig. 3a, b , Supplementary Figs. 2b , 3 ).

also in 37,734 other papers